S1 Fig. Knockdown of colon cancer-associated transcript 1 (CCAT1) enhanced sensitivity to cisplatin in SKOV3 and SKOV3/DDP cells. (A) Cell viability was monitored by MTT assay. SKOV3 and SKOV3/DDP cells were treated with different doses of cisplatin (0, 5, 10, 20, 40, 80 μM) for 24 hours. (B) IC_{50} of cisplatin in SKOV3 and SKOV3/DDP cells. (C) CCAT1 expression in SKOV3 and SKOV3/DDP cells was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). (D) CCAT1 expression was determined by qRT-PCR in SKOV3 and SKOV3/DDP cells transfected with sh-NC or sh-CCAT1. (E) Cell viability was monitored by MTT assay. SKOV3 and SKOV3/DDP cells were transfected with sh-NC or sh-CCAT1, followed by treatment with different doses of cisplatin (0-80 μM) for 24 hours. (F) IC_{50} of cisplatin in control and CCAT1 knockdown cells. Data were presented as the mean±standard deviation and performed in triplicate. *p < 0.05, **p < 0.01.